Quinupristin/Dalfopristin
Quinupristin and dalfopristin, two streptogramin antibacterials marketed in a 30:70 combination as Synercid, have received accelerated approval from the FDA for intravenous treatment of bacteremia and life-threatening infection.......
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Quinupristin/Dalfopristin
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1066
Article Code: 1066a
Date: November 19, 1999
Volume: 41
Pages: 109-110
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1066
Article Code: 1066a
Date: November 19, 1999
Volume: 41
Pages: 109-110
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)